Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7920028 | 0.78 | CCR1 (0.43) | APPKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL19356902 | 0.76 | APP (0.40) | HSD17B10APPKMT2AMEN1ALDH1A1 | |
| SCHEMBL30478722 | 0.76 | APP (0.40) | APPKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL20674169 | 0.76 | APP (0.40) | APPKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL7886143 | 0.76 | HDAC8 (0.38) | HSD17B10HDAC8KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL31752039 | 0.76 | APP (0.47) | APPKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1980691 | 0.76 | PI4KA (0.43) | APPKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL22554301 | 0.76 | HPGD (0.46) | HSD17B10APPKMT2AMEN1KDM4E | |
| SCHEMBL23119771 | 0.76 | HSD17B10 (0.39) | HSD17B10HDAC8KMT2AMAPTNPSR1 | |
| SCHEMBL15970859 | 0.76 | HDAC8 (0.50) | HSD17B10HDAC8KMT2AKDM4EENPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069571-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| EP-4387963-B1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA LTD (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4426688-B1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA LTD (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4608507-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | Neurocrine Biosciences, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12240830-B2 | Fused ring heteroaryl compounds and use thereof | BISICHEM CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| EP-4482832-A1 | 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | Les Laboratoires Servier (FR) | 2025-01-01 | — | — | EP | disclosed |
| CN-119053587-A | 5- [7- (3, 4-Dihydro-1H-isoquinoline-2-carbonyl) -1,2,3,4 tetrahydroisoquinolin-6-yl ] -1H-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing same and use thereof as pro-apoptotic agents | 法国施维雅药厂 | 2024-11-29 | — | — | CN | disclosed |
| US-20240336592-A1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA PLC (GB) | 2024-10-10 | — | — | US | disclosed |
| EP-3519409-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080262004-A1 | Tgf-Beta Inhibitors | ELI LILLY AND COMPANY (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262004-A1 | Tgf-Beta Inhibitors | ELI LILLY AND COMPANY (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262004-A1 | Tgf-Beta Inhibitors | ELI LILLY AND COMPANY (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1812450-A2 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052568-A2 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | HSD17B10 818/4885APP 3253/4885HDAC8 484/4885 |
| US-20080262004-A1 | Tgf-Beta Inhibitors | TGFB1, TGFBR1, TGFB2 | HSD17B10 2541/4885APP 468/4885HDAC8 1003/4885 |
| US-12240830-B2 | Fused ring heteroaryl compounds and use thereof | ALK, CYP3A5, SMAD3 | HSD17B10 833/4885APP 2642/4885HDAC8 1114/4885 |
| US-20260069571-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | DDR1, DDR2, TGFBR2 | HSD17B10 3418/4885APP 4463/4885HDAC8 1013/4885 |
| US-20240336592-A1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | DDR1, DDR2, DDRGK1 | HSD17B10 4152/4885APP 3422/4885HDAC8 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.